Drug or technology

Ifinatamab deruxtecan

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 7, 2026 · INTERVENTIONAL STUDY

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record for an expanded access program with no results posted; it describes a planned intervention pathway, not clinical evidence of efficacy or safety.

PreliminaryExtensive Stage Small Cell Lung Cancer Ifinatamab deruxtecan SCLC

Reported

Study typeExpanded Access Program

Target populationExtensive-stage SCLC, ≥2 prior lines of tre…

AUG 5, 2026 · PHASE 3 TRIAL

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

ClinicalTrials.gov

Phase 3 randomized trial of ifinatamab deruxtecan versus physician's choice in relapsed SCLC; registry record with no results posted, so efficacy and safety remain unreported.

PreliminaryNCT06203210 Amrubicin Topotecan

Reported

Planned enrollment540

Primary endpointOverall Survival (OS), from date of randomi…

PhasePhase 3